You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Dr. Oz praised GLP-1s from Eli Lilly’s lab, where he said MFN agreements have drastically cut the price of obesity drugs. Problem is, at least Lilly’s GLP-1s are exempt from the MFN agreements (see below). But who am I to correct people? I incorrectly attributed an AEI post to another conservative think tank in this newsletter last week. Send news tips and correction requests to [email protected] or John_Wilkerson.07 on Signal.
Novo’s (potentially) big win
STAT has written about how Eli Lilly and Novo Nordisk benefited from their deals with the Trump administration to cut obesity drug costs for seniors. It turns out, Novo might have gotten an additional sweetener.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
